Germany may have acquired a reputation for having a challenging environment with which to operate a digital health business, with critics pointing to issues such as a strict data protection regime and the nature of the German health insurance sector. In this article however, Marc L. Holtorf, Partner and Head of German Intellectual Property and Life Sciences at Pinsent Masons Germany LLP, presents a more positive view of the status of digital health in Germany, and looks at some of the initiatives being taken by the German federal Government to support digital health. / read more

Cori Goldberg, Chaula Mehta, and Krishna Kavi of Norton Rose Fulbright reflect on the US Food and Drug Administration’s (‘FDA’) enforcement action relating to the promotion of prescription drugs and medical devices online in 2016, reflecting on the draft guidance issued and what 2017 - and a Trump presidency - might hold. / read more